secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001193125-25-055666
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA Royalty reports Q4/FY2024 revenue $28.5M, net loss $13.8M; portfolio doubled to 120+ assets
--------------------------------------------------------------------------------

- Total revenue $8.7M Q4, $28.5M FY2024 (vs $1.8M and $4.8M in 2023); net loss $4.0M Q4, $13.8M FY2024.
- Cash and equivalents $106.4M at Dec 31, 2024; cash receipts totaled $46.3M in FY2024.
- Doubled royalty portfolio to over 120 assets via five 2024 transactions: Twist ($15M), Daré ($22M), Talphera ($8M), Kinnate ($2.5879/sh + CVR), Pulmokine ($20M).
- FDA approvals for Day One's OJEMDA and Zevra's MIPLYFFA; milestone payments received from both.
- Non-cash credit losses $30.9M FY2024 (Agenus, Aronora, Talphera); management sees path to cash flow positive from royalties alone in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312525055666/0001193125-25-055666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312525055666/d903231d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-055666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer